{"disease":{"id":"leiomyosarcoma","name":"Leiomyosarcoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":1,"trial_count":12},"drugs":{"marketed":[{"drug_id":"yondelis","indication_name":"Leiomyosarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yondelis","company_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase Src, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"trabectedin","indication_name":"Leiomyosarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yondelis","generic_name":"TRABECTEDIN","company_name":"Janssen Prods","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase Src","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Yondelis works by binding to DNA and causing interstrand crosslinks, thereby inhibiting cancer cell growth."}],"pipeline":[{"drug_id":"ontorpacept-tti-621","indication_name":"Leiomyosarcoma","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ontorpacept (TTI-621)","generic_name":"ontorpacept-tti-621","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Ontorpacept (TTI-621) will be administered by intravenous infusion.","quality_score":null,"revenue":null,"mechanism":"Ontorpacept (TTI-621) will be administered by intravenous infusion."}],"offLabel":[],"totalMarketed":2,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT06244251","title":"Comparison Between Laparoendoscopic Single-site Surgery and Multi-port Laparoscopy in Treating Uterine Fibroids","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"West China Second University Hospital","has_results":false},{"nct_id":"NCT06526897","title":"Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1582,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT07432932","title":"Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT00346164","title":"Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":588,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT06088290","title":"Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"PharmaMar","has_results":false},{"nct_id":"NCT05269355","title":"A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":359,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT04031677","title":"Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT05094804","title":"A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":172,"lead_sponsor_name":"OncoResponse, Inc.","has_results":false},{"nct_id":"NCT04055220","title":"Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas","phase":"NA","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT02601209","title":"Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":151,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02997358","title":"Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT02180867","title":"Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":140,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07169344","title":"Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT06975293","title":"STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":107,"lead_sponsor_name":"STORM Therapeutics LTD","has_results":false},{"nct_id":"NCT04383119","title":"Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Italian Sarcoma Group","has_results":false},{"nct_id":"NCT05227326","title":"AOH1996 for the Treatment of Refractory Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":92,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03851614","title":"Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":90,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT05827614","title":"Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":85,"lead_sponsor_name":"Boundless Bio, Inc.","has_results":false},{"nct_id":"NCT04535271","title":"Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Sarcoma Oncology Research Center, LLC","has_results":false},{"nct_id":"NCT04996004","title":"A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":76,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05432791","title":"Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":74,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06498648","title":"Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":74,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02584309","title":"Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT04200443","title":"Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT01653028","title":"Alisertib in Treating Patients With Advanced or Metastatic Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05836571","title":"Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute LAO","has_results":false},{"nct_id":"NCT02203760","title":"Pazopanib Vs. Pazopanib Plus Gemcitabine","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":58,"lead_sponsor_name":"North Eastern German Society of Gynaecological Oncology","has_results":false},{"nct_id":"NCT03899805","title":"A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":true},{"nct_id":"NCT04811196","title":"A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT01532687","title":"Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":true},{"nct_id":"NCT07405346","title":"A Trial for Advanced Leiomyosarcoma With Human Organoid-guided Personalized Efficacy","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":50,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT07076186","title":"Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01614795","title":"Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06849986","title":"IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03761095","title":"A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"PTC Therapeutics","has_results":false},{"nct_id":"NCT05649956","title":"Letrozole in Uterine Leiomyosarcoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"GOG Foundation","has_results":false},{"nct_id":"NCT00112463","title":"Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02923778","title":"Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07173972","title":"Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT01533207","title":"Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":38,"lead_sponsor_name":"Gynecologic Oncology Group","has_results":true},{"nct_id":"NCT03536780","title":"Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":38,"lead_sponsor_name":"Gachon University Gil Medical Center","has_results":false},{"nct_id":"NCT03074318","title":"Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":35,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT03241745","title":"A Study of Nivolumab in Selected Uterine Cancer Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true},{"nct_id":"NCT04242238","title":"Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT06749600","title":"Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Azienda USL Reggio Emilia - IRCCS","has_results":false},{"nct_id":"NCT03526679","title":"Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"National Taiwan University Hospital","has_results":true},{"nct_id":"NCT05711615","title":"Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03718091","title":"M6620 (VX-970) in Selected Solid Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Massachusetts General Hospital","has_results":true},{"nct_id":"NCT03989596","title":"Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Maria Sklodowska-Curie National Research Institute of Oncology","has_results":false},{"nct_id":"NCT06571734","title":"XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":29,"lead_sponsor_name":"Northwestern University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}